During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Rondo Therapeutics, a privately held biopharmaceutical immuno-oncology company pioneering the development of next-generation ...

See a doctor who has experience with it. You’ll find dermatologists who have experience with cutaneous T-cell lymphoma at Find a Dermatologist. Click on "Filters". Select "Any condition" and choose ...

Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case ...

A new study shows how an anticancer drug triggers an “outside in” signal that gets it sucked into a cancer cell. The work, published Jan. 29 in Nature Communications, reveals a new signaling mechanism ...

George Coukos, MD, PhD, Department of Oncology, University Hospital of Lausanne, Rue du Bugnon 46, Lausanne 1011, Switzerland; e-mail: [email protected]. If you have the appropriate software installed ...

Anti-CD19 chimeric antigen receptor (CD19-CAR)-engineered T cells are approved therapeutics for malignancies. The impact of the hinge domain (HD) and the transmembrane domain (TMD) between the ...

“If we can properly nourish our T cell soldiers in the lab by convincing them to eat the right kind of food, they are better prepared to respond to signals in the body and live much longer. We might ...

Paperbacks don’t break the bank, and can be put aside if ... Second, any thorough investigation needs to ask whether those who missed the signals did so because they did not want to ask ...